Format

Send to

Choose Destination
Curr Opin Immunol. 1996 Oct;8(5):651-7.

Peptide-based cancer vaccines.

Author information

1
Department of Immunohaematology, University Hospital of Leiden, The Netherlands. ihbsecr@euronet.nl

Abstract

The application of molecularly defined vaccines composed of a limited number of tumor-specific T cell epitopes has resulted in protective antitumor T cell immunity in several mouse tumor models. The first encouraging results with such vaccines have been obtained in human beings. The development of the next generation of rationally designed vaccines that are both effective and safe for application in a clinical setting requires comparison of different modes of delivery of tumor-associated T cell epitopes in multiple epitope constructs.

PMID:
8902390
DOI:
10.1016/s0952-7915(96)80081-1
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center